Oscar Health (NYSE:OSCR) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Oscar Health (NYSE:OSCR) had its target price hoisted by equities research analysts at Robert W. Baird from $15.00 to $19.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Robert W. Baird’s price objective would suggest a potential downside of 10.72% from the company’s previous close.

A number of other analysts have also weighed in on OSCR. Barclays raised their price target on shares of Oscar Health from $18.00 to $21.00 and gave the company an “equal weight” rating in a report on Thursday. UBS Group reissued a “neutral” rating and issued a $15.00 price target on shares of Oscar Health in a report on Wednesday, February 11th. Raymond James Financial raised shares of Oscar Health from a “market perform” rating to an “outperform” rating and set a $18.00 price target for the company in a report on Thursday, February 12th. Wolfe Research started coverage on shares of Oscar Health in a report on Tuesday. They issued a “peer perform” rating for the company. Finally, Jefferies Financial Group raised shares of Oscar Health from an “underperform” rating to a “hold” rating and raised their price target for the company from $10.00 to $16.00 in a report on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Oscar Health has a consensus rating of “Hold” and an average price target of $18.22.

Oscar Health Stock Performance

Shares of Oscar Health stock opened at $21.28 on Thursday. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.96 and a quick ratio of 0.96. The firm has a market cap of $6.34 billion, a P/E ratio of -36.07, a P/E/G ratio of 2.78 and a beta of 2.34. The firm has a 50 day simple moving average of $14.43 and a 200 day simple moving average of $15.29. Oscar Health has a fifty-two week low of $10.69 and a fifty-two week high of $23.80.

Oscar Health (NYSE:OSCR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.11 by $0.96. The business had revenue of $4.65 billion during the quarter, compared to analyst estimates of $4.90 billion. Oscar Health had a negative net margin of 0.30% and a negative return on equity of 3.73%. Oscar Health’s revenue for the quarter was up 52.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.92 earnings per share. Sell-side analysts predict that Oscar Health will post 0.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Oscar Health news, CEO Mark T. Bertolini bought 1,000,000 shares of the stock in a transaction on Monday, April 6th. The stock was purchased at an average price of $11.92 per share, with a total value of $11,920,000.00. Following the acquisition, the chief executive officer owned 10,196,876 shares of the company’s stock, valued at approximately $121,546,761.92. The trade was a 10.87% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 24.39% of the company’s stock.

Institutional Trading of Oscar Health

A number of institutional investors have recently bought and sold shares of OSCR. BIT Capital GmbH grew its holdings in Oscar Health by 545.0% during the 4th quarter. BIT Capital GmbH now owns 6,186,267 shares of the company’s stock worth $88,897,000 after acquiring an additional 5,227,152 shares during the period. American Century Companies Inc. grew its holdings in Oscar Health by 89.0% during the 3rd quarter. American Century Companies Inc. now owns 5,298,340 shares of the company’s stock worth $100,298,000 after acquiring an additional 2,495,691 shares during the period. Farallon Capital Management LLC grew its holdings in Oscar Health by 146.5% during the 3rd quarter. Farallon Capital Management LLC now owns 3,639,000 shares of the company’s stock worth $68,886,000 after acquiring an additional 2,163,000 shares during the period. Morgan Stanley grew its holdings in Oscar Health by 42.8% during the 4th quarter. Morgan Stanley now owns 6,814,046 shares of the company’s stock worth $97,918,000 after acquiring an additional 2,043,758 shares during the period. Finally, Thrive Capital Management LLC grew its holdings in Oscar Health by 33.4% during the 4th quarter. Thrive Capital Management LLC now owns 6,343,617 shares of the company’s stock worth $85,258,000 after acquiring an additional 1,588,395 shares during the period. Institutional investors and hedge funds own 75.70% of the company’s stock.

About Oscar Health

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.